TG Therapeutics

is a biopharmaceutical company focused on the development of
novel treatments for B-cell malignancies and autoimmune diseases.

Click for full image >>

For Investors

NASDAQ: TGTX

News & Events

6.18.18

TG Therapeutics Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA)

6.20.18

TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47 / Anti-CD19 Bispecific Antibody

Quick Links